Only a small fraction of the drugs developed in laboratories ever make it to the clinical trial stage. Before a clinical trial begins, the drug must be evaluated in pre-clinical laboratory studies ...
Innovative strategists in big pharma are exploring a new way to claw back some of these costs, and expand the number of new therapies that go through to the development and clinical trial stage.